In summary, our studies demonstrate that elevated MEKK3 activity is causal for CCM lesion formation in the mouse models, and suggest that partial inhibition of MEKK3 expression and/or activity is a promising therapeutic strategy to prevent and/or treat CCM disease. The gene discussed is MAP3K3; the disease is cerebral cavernous malformation.